scholarly journals Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis

2007 ◽  
Author(s):  
Jae-Won Seol ◽  
Atul Chaudhari ◽  
You-Jin Lee ◽  
Hyung-Sub Kang ◽  
In-Shik Kim ◽  
...  
Keyword(s):  
Transmembrane Potential ◽  
Mitochondrial Transmembrane Potential ◽  
Induced Apoptosis

MEK1 Inhibition and Arsenic Trioxide Synergize To Induce Apoptosis of Acute Myeloid Leukemia Blasts.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3397-3397
Author(s):  
Paolo Lunghi ◽  
Luigi Salvatore ◽  
Nelida Noguera ◽  
Pier Giuseppe ◽  
Francesco Lo ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Arsenic Trioxide ◽  
Myeloid Leukemia ◽  
Transmembrane Potential ◽  
Combined Treatment ◽  
Additive Effect ◽  
Mitochondrial Transmembrane Potential ◽  
Genetic Characteristics ◽  
Induced Apoptosis ◽  
Acute Myeloid

Abstract We recently demonstrated that the combined treatment with PD184352, a highly selective inhibitor of MEK1 phosphorylation and activation (kindly provided to us by Dr J. S. Sebolt-Leopold, Cancer Molecular Sciences, Pfizer Global Research & Development, Ann Arbor, MI) and arsenic trioxide (ATO) strikingly potentiates apoptotic cell death induced by ATO in K562 and NB4 leukemic cells through the up-regulation of the proapoptotic p53AIP1 protein (p53-regulated Apoptosis-Inducing Protein 1), via p73 activation (Blood104: 519–525, 2004). Moreover, we showed that MEK1 inhibition sensitizes both parental and arsenic resistant NB4 cell lines to ATO-induced apoptosis through the MEK1 inhibition-mediated dephosphorylation of Bad, increasing its capacity to heterodimerize with Bcl-xL and Bcl-2 thereby blocking theirs antiapoptotic functions (ASH 2003, Abstract 61). p53AIP1 interacts with Bcl-2, affecting p53AIP1-mediated apoptosis through regulation of the mitochondrial transmembrane potential, thus supporting a model in which both pathways (p73-p53AIP1 and Bad phosphorylation) contribute to ATO induced apoptosis and its enhancement by MEK1 inhibitor co-treatment. Collectively, our results prompted us to investigate whether the combination of PD184352 and ATO was effective in inducing apoptosis of primary acute myeloid leukemia (AML) blasts. Twenty primary AML samples with different FAB classification were analyzed at diagnosis. Immunological and genetic characteristics were defined. Primary AML samples were cultured in presence of escalating doses of PD184352 (0.1–20 μM), ATO (0.125–10 μM) or combinations of the 2 agents at a 1:1 ratio (0.25/0.25, 0.5/0.5, 1/1, 1.5/1.5, 2/2). After 48 h of treatment the cells were harvested for mitochondrial transmembrane potential, annexin V and sub-G1 DNA content detection. Combination Index (CI) plots were then generated using the Chou-Talalay method and Calcusyn software (Biosoft, Ferguson, MO). CI less than 1.0 indicates synergism; CI = 1.0 indicates additive effect; CI more than 1.0 indicates antagonistic effect. Interestingly, MEK1 inhibition strikingly increased the apoptosis induced by ATO in sixteen of twenty primary AML samples analyzed. Isobologram analysis confirmed the additive or synergistic nature of this interaction. Five responder patients showed additive effect (one M0, two M2, two M4), eleven synergism (one M1, three M2, three M3, two M4, two M5). In the responsive AML samples the combined treatment with PD184352 and ATO strikingly potentiated loss of mitochondrial transmembrane potential induced by ATO. Treatment with MEK1 inhibitor down-modulated the steady level of ERK and Bad phosphorylation and prevented theirs phosphorylation in rensponse to ATO treatment. Moreover, p53AIP1 expression was enhanced after PD184352 plus ATO treatment compared to ATO alone. In conclusion these results demonstrated a cooperation between these two agents in this setting, and could provide an experimental basis for combined or sequential MEK1 inhibition plus ATO therapy in AML.

Mesenchymal stem cells-conditioned medium protects PC12 cells against 2,5-hexanedione-induced apoptosis via inhibiting mitochondria-dependent caspase 3 pathway

2016 ◽  
Vol 33 (2) ◽  
pp. 107-118 ◽  
Author(s):  
Shuang-yue Li ◽  
Yuan Qi ◽  
Shu-hai Hu ◽  
Feng-yuan Piao ◽  
Huai Guan ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cytochrome C ◽  
Conditioned Medium ◽  
Pc12 Cells ◽  
Caspase 3 ◽  
Transmembrane Potential ◽  
Mitochondrial Transmembrane Potential ◽  
Neural Cells ◽  
Induced Apoptosis

Studies suggested that the conditioned medium of mesenchymal stem cells (MSC-CM) inhibited the increased apoptosis in various cells. However, there are no reports underlying the protection of MSC-CM against 2,5-hexanedione (HD)-induced apoptosis in neural cells. In the present study, the viability was observed in PC12 cells that received HD alone or with MSC-CM by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Apoptosis was estimated by Hoechst 33342 staining and flow cytometry. Mitochondrial transmembrane potential was examined by rhodamine 123. Moreover, we investigated the expression of Bax and Bcl-2, cytochrome c translocation, and caspase 3 activity by real-time polymerase chain reaction, Western blot, and immunochemistry. Nerve growth factor (NGF) was examined in MSCs and MSC-CM. Our results showed that MSC-CM promoted cell survival and reduced apoptosis in HD-exposed PC12 cells. Moreover, MSC-CM significantly reversed disturbance of Bax and Bcl-2, ameliorated disruption of mitochondrial transmembrane potential, and reduced release of cytochrome c and activity of caspase 3 in HD-exposed PC12 cells. In the meantime, NGF was detected in MSCs and MSC-CM. These findings demonstrate that MSC-CM protects against HD-induced apoptosis in PC12 cells via inhibiting mitochondrial pathway. Our results indicate that NGF in MSC-CM may be involved in the protection of MSC-CM against HD-induced apoptosis. Our study clarifies the protection of MSC-CM on HD neurotoxicity and its underlying mechanism.

Sign in / Sign up

Export Citation Format

Share Document